🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Eva Blondeaux presenting at #ESMO24 data on breastfeeding 🤱 4732 BRCAm stage I-III BC pts > 659 had a pregnancy after BC diagnosis > 474 delivered a child > 110 (23.2%) pts breastfed 💥 no difference in DFS or OS was observed OncoAlert ESMO - Eur. Oncology

Super Eva Blondeaux from Ospedale San Martino Genova 🇮🇹 presenting at #ESMO24 further evidence on safety of breastfeeding after BC in young BRCA carriers 👩‍🍼 178 pts, 7y fup: 29% BC events in breastfeeding pts 37% events in non-breastfeeding pts No diff in 7y DFS Matteo Lambertini, MD PhD OncoAlert

Now out in ESMO Open our study on characteristics and clinical outcomes of breast cancer in a 🌎cohort of 4,628 young BRCA carriers🧬 according to tumor histology ➡️Low incidence of lobular, having higher disease stage and more BRCA2️⃣ PVs OncoAlert authors.elsevier.com/sd/article/S20…

Two studies presented by Eva Blondeaux from 🇮🇹 Ospedale San Martino Genova and and Fedro Peccatori MD, PhD from 🇮🇹 IEO at the ESMO - Eur. Oncology congress (#ESMO24) show no increase in recurrence or new cancers in women who #breastfeed after being treated for #breastcancer. dlvr.it/TDN1n6

New study now out in ESMO Open: Characteristics and clinical outcomes of #BreastCancer in young #BRCA carriers according to tumor histology. 🔓pubmed.ncbi.nlm.nih.gov/39288653/#full… ✍️Elisa Agostinetto Guilherme Nader Marta Nerea Lopetegui-Lia, MD Ann Partridge MD, MPH @fedgiugliano Kathryn Ruddy Fabio Puglisi

Thrilled that the VOICE study was awarded the Gilead Sciences Fellowship Program 🎉 Thanks to Eva Blondeaux Massimo Di Maio Francesco Perrone for collaborating on this research project! Istituto Nazionale Tumori Pascale Scuola Superiore Meridionale AIOM #BreastCancer #FinancialToxicity #BCSM #Survivorship

Final tweet from #AIOM24 to congratulate Dr. Eva Blondeaux from Università di Genova Ospedale San Martino Genova for winning the most important recognition in 🇮🇹 for a young oncologist, the #MarcoVenturini award lecture for our JAMA paper on safety of pregnancy in #BRCA carriers 👏 OncoAlert

#MarcoVenturini award is not only a recognition for the paper, but to the entire research path, started in Università di Genova by Lucia Del Mastro and Matteo Lambertini, MD PhD and continued with Eva Blondeaux. I couldn't be more proud for our friend Eva Blondeaux for this well deserved award! 🎖️

Other crucial evidences from the 🌍 BRCA BCY study Presented at #SABCS24 by Matteo Lambertini, MD PhD the role of RRM and RRSO in young pts w previous diagnosis of BC: RRM: ⬆️ OS, DFS and BCFI RRSO: ⬆️ OS, DFS and BCFI Congrats👏🏼👏🏼👏🏼 Università di Genova Ospedale San Martino Genova Eva Blondeaux OncoAlert

I am proud to share the Gruppo Italiano Mammella's effort to explore patient attrition and main factors across subtypes. Thanks to all co-authors, especially Eva Blondeaux, for her extraordinary competence and commitment.

Now out in Journal of Clinical Oncology the results of our global collaboration🌎 led by Matteo Lambertini, MD PhD showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis - a thread👇🏻🧵 OncoAlert ascopubs.org/doi/10.1200/JC…

As emphasized by Journal of Clinical Oncology Editors, these results show the power of #genetic information in improving outcomes: we should reinforce our efforts to offer testing broadly to increase early #diagnoses and improve #prognosis of young patients. Congratulations to all co-authors!

Published in JNCI our analysis assessing the prognosis of patients considered at high risk of recurrence according to #monarchE and #NATALEE trials inclusion criteria! 📄: academic.oup.com/jnci/advance-a… Eva Blondeaux Matteo Lambertini, MD PhD Lucia Del Mastro OncoAlert Main findings here👇🏼

Important analyses. Thinking about treatment selection by actual prognosis/risk, and not by study eligibility, is a long standing approach in breast cancer. As was discussed SGBCC St Gallen last month, it should be applied to decision making in adjuvant CDK46i selection, too.

New Journal of Clinical Oncology📰 looking at clinical behavior of #BreastCancer in young BRCA carriers and prediagnostic awareness of germline BRCA status 🔓pubmed.ncbi.nlm.nih.gov/39993249/ ✍️Matteo Lambertini, MD PhD Ann Partridge MD, MPH Eva Blondeaux Elisa Agostinetto Franzoi Maria Alice Jyoti Bajpai Michail ignatiadis

The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅Prognostic implications of risk definitions from the monarchE and NATALEE trial academic.oup.com/jnci/advance-a… ✅Evaluating

🔬 Another major step forward in managing young BRCA carriers with prior breast cancer published in Lancet Oncology Thanks to all that have made this study possibile!

Live from #ASCO25…the Italian queen Angela Toss 🇮🇹 presenting data from the #BRCABCYcollaboration on association between type and location of pathogenic variants in the #BRCA genes and outcomes in young #BreastCancer patients OncoAlert AIOM ASCO Eva Blondeaux Università di Genova

Dear Colleagues at #ASCO25 An honor to present Angela Toss Presenting on Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with #BreastCancer Eva Blondeaux Cynthia Villarreal-Garza, MD DSc Carmine De Angelis Elisa Agostinetto Breast Cancer

More data from the #BRCABCYcollaboration at #ASCO25 presented by Paola Zagami, MD showing the benefit of ovarian function suppression as adjuvant endocrine therapy in young #BRCA carriers with #BreastCancer OncoAlert Eva Blondeaux ASCO